Blood test detects lung cancer up to 5 years before scans, Personalis and University College London study finds

Montefiore Einstein sees lowest rate of late-stage lung cancer diagnoses in surrounding community

For the first time in decades, more people in the Bronx nearby Montefiore Einstein Comprehensive Cancer Center are being diagnosed with stage 1, versus stage 4 lung cancer.

December 05, 2025

Vol.51 No.44

Clinical Roundup

Nuvalent announces positive topline pivotal data from ALKOVE-1 trial of neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC

Nuvalent, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 phase I/II clinical trial.

November 21, 2025

Vol.51 No.43

Drugs & Targets

FDA approves Hyrnuo for HER2-mutated NSCLC

FDA has approved Hyrnuo (sevabertinib), an oral, reversible, tyrosine kinase inhibitor, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.

November 21, 2025

Vol.51 No.43

Drugs & Targets

Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection

Microsoft and Qure.ai announced a collaboration that will streamline deployment of Qure.ai solutions to hospitals and health systems across the U.S.

November 21, 2025

Vol.51 No.43

City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure

As we mark Lung Cancer Awareness Month, it is a time to acknowledge that screening and prevention are vital, and equally crucial is ensuring that patients have access to state-of-the-art care and research. Herein, I spotlight some of the transformative work underway at City of Hope.

November 07, 2025

Vol.51 No.41

By Ravi Salgia

Cancer Policy

Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients

FDA announced six additional awardees under the Commissioner’s National Priority Voucher pilot program, which aims to accelerate review time for applications that are deemed to be advancing U.S. “national priorities” (The Cancer Letter, Oct. 24, June 20, 2025).

November 07, 2025

Vol.51 No.41

By Jacquelyn Cobb

Blood test detects lung cancer up to 5 years before scans, Personalis and University College London study finds

YOU MAY BE INTERESTED IN

Montefiore Einstein sees lowest rate of late-stage lung cancer diagnoses in surrounding community

Nuvalent announces positive topline pivotal data from ALKOVE-1 trial of neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC

FDA approves Hyrnuo for HER2-mutated NSCLC

Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection

City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure

Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients

Renew today!

Subscriber content

Never miss an issue!

Login